Clinical decision-support only. For use by licensed dental professionals. Not a substitute for professional judgment or a complete drug reference. Always verify with primary sources.
← Back to search
Medication

Sorafenib

Targeted therapy (multikinase/antiangiogenic inhibitor)

Brand names: Nexavar

Oral health effects

  • MRONJ / mucositis / dysgeusia

    Associated with osteonecrosis risk, oral mucosal sensitivity, and taste disturbance.

    Clinical management: MRONJ precautions; supportive mucosal care.

  • Delayed wound healing after surgery or extractions

    The label warns of impaired wound healing and advises withholding sorafenib for at least 10 days before elective surgery and until adequate healing afterwards.

    Clinical management: Coordinate elective extractions, periodontal or implant surgery with the oncologist so the drug can be paused per label timing; routine scaling and non-surgical care can generally continue. Note the separate MRONJ risk.

  • Bleeding tendency (including gingival bleeding)

    The label warns that an increased risk of bleeding may occur with sorafenib; serious bleeding events were seen in trials.

    Clinical management: Expect more gingival bleeding during probing and scaling; check recent platelet counts before invasive procedures, use local hemostatic measures, and report spontaneous gum bleeding to the oncology team.

Sources

  1. AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaws: 2022 Update. Ruggiero SL, Dodson TB, et al.. Journal of Oral and Maxillofacial Surgery, 2022.
  2. Sorafenib prescribing information (FDA label) Torrent Pharmaceuticals Limited / DailyMed, 2026.